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Abstract
Background: Probiotics have beneficial effects in rodent models of Clostridium difficile (C. diffiicle)-induced colitis.
The spore forming probiotic strain Bacillus Coagulans GBI-30, 6086 (BC30) has demonstrated anti-inflammatory and
immune-modulating effects in vitro. Our goal was to determine if BC30 improved C. difficile-induced colitis in mice.
Starting on study day 0, female C57BL/6 mice were dosed by oro-gastric gavage for 15 days with vehicle (saline) or
BC30 (2 × 10
9 CFU per day). Mice in the C. difficile groups received an antibiotic mixture (study days 5 to 8 in the
drinking water), and clindamycin (10 mg/kg, i.p., on study day 10). The C. difficile strain VPI 10463 was given by
gavage at 10
4 CFU to induce colitis on day 11. On day 16, stools and colons were collected for further analyses.
Results: All mice treated with BC30 survived on study day 13, while two mice treated with vehicle did not survive.
On day 12, a significant difference (p = 0.0002) in the percentage of mice with normal stools (66.7%) was found in
the BC30/C. difficile group, as compared to the vehicle/C. diffcile group (13.0%). On study day 16, 23.8% of mice
treated with BC30 had normal stools, while this value was 0% with vehicle treatment (p value = 0.0187). On this
day, the stool consistency score for the BC30/C. difficile group (1.1 ± 0.2) was significantly lower (p < 0.05) than for
the vehicle/C. difficile cohort (1.9 ± 0.2). BC30 modestly attenuated the colonic pathology (crypt damage, edema,
leukocyte influx) that was present following C. difficile infection. Colonic MIP-2 chemokine contents (pg/2 cm colon)
were: 10.2 ± 0.5 (vehicle/no C. difficile), 24.6 ± 9.5 (vehicle/C. difficile) and 16.3 ± 4.3 (BC30/C. difficle).
Conclusion: The probiotic BC30 improved some parameters of C. difficile-induced colitis in mice. BC30 prolonged
the survival of C. diffiicle infected mice. Particularly, this probiotic improved the stool consistency of mice, in this
infectious colitis model.
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Background
Clostridium Difficile (C. difficile) infection can cause noso-
comial-related diarrhea [1]. The spectrum of C. difficile-
associated disease (CDAD) ranges from mild antibiotic
associated diarrhea to severe (or even life threatening)
pseudomembranous colitis [1]. CDAD is caused by the
actions of two exotoxins (toxin A and toxin B), which are
produced by pathogenic strains of C. difficile [2,3].
Previous data suggests that toxin A can activate the
nuclear factor-kappa B (NF-B) signal transduction system
in monocytes and colonic epithelial cells [4,5]. This activa-
tion of NF-B leads to secretion of a key pro-inflammatory
chemokine (IL-8) and subsequently to neutrophil influx
into the colonic tissue [4,5]. Neutrophils play a key role
in the pathogenesis of CDAD, both in humans and in
mice [6].
CDAD is often treated successfully with standard anti-
biotics such as vancomycin, or metronidazole [7,8]. How-
ever, recurrence occurs in many patients [6,8]. Some
clinical studies have focused on combined treatment with
vancomycin and probiotics such as Saccharomyces boular-
dii for recurrent disease [8-11]. Therefore, initial treatment
regimens with probiotics, or their use for prevention of
recurrent disease, may be attractive as part of the overall
therapeutic strategy for CDAD [8-11].
Probiotics are live microorganisms which, when
ingested, can confer health benefits [12]. Typically, probio-
tics include various strains of Lactobacillus and/or Bifido-
bacteria species. They exist as either single entities or as
combination products (e.g., VSL #3) [13,14]. Other known
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(E. coli) strains like Nissle 1917 and M-17 [13,15].
Mechanisms explaining the potential role of probiotics as
anti-colitis therapies have been reviewed in detail else-
where [13]. Recently, our laboratory has shown that a
non-pathogenic strain of E. coli can inhibit colitis in mice
by immunomodulating the NF-B signal transduction sys-
tem and inhibiting associated pro-inflammatory cytokines
[15]. Of note, a recent paper found that Lactobacillus acid-
ophilus was effective for treating CDAD in mice [16].
Of direct relevance to this study, the novel spore form-
ing probiotic strain GanedenBC
30 (Bacillus coagulans
GBI-30, 6086) is relatively resistant to extreme tempera-
tures, as well as stomach acidity, digestive enzymes and
bile salts [17]. Bacillus Coagulans GBI-30 (BC30) has been
used for human consumption to ameliorate symptoms in
various gastrointestinal disorders, as well as an immuno-
modulating agent in ex-vivo viral challenge, and in vivo
human immunodeficiency virus research [17,18].
Preliminary research to articulate its mechanisms of
action demonstrated anti-inflammatory and immunomo-
dulating effects in vitro [19]. Therefore, as a logical
extension to this in vitro evaluation, we evaluated the
effectiveness of BC30 for inhibiting C. difficile induced
colitis in mice. Since NF-B activation and chemokine
secretion also play important roles in the pathogenesis of
CDAD, we also evaluated the effects of BC30 on this cri-
tical transcription factor, as well as MIP-2, in this murine
CDAD model [4-7].
Results
BC30 prolongs mouse survival after the administration of
C. difficile
Figure 1 shows an overview of the key events associated
with the C. difficile induced colitis model that was used
for this study. As shown in Figure 2, all mice treated with
BC30 (100%) survived on study day 13, while 2 mice trea-
ted with vehicle did not survive on that day (92.3% survi-
val). By day 14, 21/23 mice survived in the BC30/C.
difficile treatment group, while 23/26 mice survived in the
Vehicle/C. difficile treatment group. As expected, all mice
(6/6) that did not receive C. difficile survived for the dura-
tion of the study. Therefore, the cumulative survival rates
in the study were: 100% (Vehicle/no C. difficile), 88.5%
(Vehicle/C. difficile) and 91.3% (BC30/C. difficile). How-
ever, there was not a statistically significant difference in
the survival rate between any of the treatment groups.
Despite the delay in mortality rate in the BC30 treat-
ment group, there were similar body weight profiles in
both C. difficile treatment groups. Mice in these treat-
ment groups lost weight (by approximately 10%) between
days 11 and 14, and then subsequently began to gain
weight. There were no differences in the body weights
(grams) on day 16: 19.5 ± 0.4 (Vehicle/C. difficile)a n d
18.8 ± 0.4 (BC30/C. difficile). In contrast, mice that did
not receive C. difficile gained weight during the study
period (body weight on day 16 = 20.6 ± 0.5 grams).
BC30 treatment significantly improves the stool
consistency in C. difficile infected mice
Figure 3 illustrates that 13% of mice in the Vehicle/C. diffi-
cile treatment group had normal stools on day 12; while
67% of the probiotic (BC30) treated mice still had normal
stools. On days 13 and 14, altered stool consistency was
seen in both C. difficile treatment groups. However, evi-
dence of a normal stool was seen in 24% of BC30 treated
mice on day 16, but no vehicle treated animals (0%)
showed a normal stool consistency on that day. Statistical
significance (p < 0.05) between the vehicle and BC30 treat-
ment groups was found on study days 12 and 16.
Moreover, as shown in Figure 4, the mean stool con-
sistency score (day 16) was significantly lower in BC30/
C. difficile treated mice (1.1 ± 0.2) than in correspond-
ing Vehicle/C. difficile treated animals (1.9 ± 0.2).
BC30 slightly attenuates indices of C. difficile-induced
colonic pathology
The distal colonic weight was significantly increased in
mice treated with vehicle plus C. difficile. However, treat-
ment with the probiotic (BC30) only slightly normalized
the colonic weight. Values (mg/cm colon) on day 16 were:
17.4 ± 0.8 (Vehicle/no C. difficile), 26.3 ± 0.7 (Vehicle/C.
difficile) and 25.4 ± 0.6 (BC30/C. difficile). A statistically
s i g n i f i c a n td i f f e r e n c e( p<0 . 0 5 )w a sf o u n db e t w e e nt h e
Vehicle/no C. difficile and Vehicle/C. difficile treatment
groups, but not between the two C. difficile treated groups
of mice.
Representative histology pictures are shown in Figure 5.
C. difficile infection caused altered colonic histopathology.
Specifically, crypt damage, submucosal edema and the
influx of inflammatory cells in the lamina propria and sub-
mucosa were evident in these mice (panel B). Overall,
BC30 treatment resulted in a modest attenuation of the
colonic histological pathology observed in Vehicle/C. diffi-
cile treated mice (panel C). The overall colonic histology
scores on study day 16 were: 2.55 ± 0.39 (Vehicle/No C.
difficile), 5.19 ± 0.22 (Vehicle/C. difificile) and 4.96 ± 0.34
(BC30/C. difficile). A statistically significant difference (p <
0.05) was found between the Vehicle/no C. difficile and
Vehicle/C. difficile treatment groups, but not between the
two C. difficile treated groups of mice.
BC30 attenuates colonic NF-kB p65 binding and
chemokine content in C. diffiicle infected mice
As shown in Figure 6, there were reductions in the colo-
nic nuclear binding of p65 and the colonic MIP-2 con-
t e n tr e s p e c t i v e l y ,w h e nm i c ew e r et r e a t e dw i t hB C 3 0 .
The mean absorbance values for p65 binding were:
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Page 2 of 9Figure 1 Study Overview. This figure shows an overview of the key events associated with the Clostridium difficile induced colitis model that
was used for this study. Female C57BL/6 mice were dosed during study days 0 through 15 with 2 × 10
9 CFU of BC30, or vehicle (0.9% saline).
On study days 5 through 8, mice were given an antibiotic coktail in the drinking water as described in the Methods section. On day 10,
clindamycin was administered i.p. at a dose of 10 mg/kg. On day 11, mice received either Clostridium difficile (designated as C diff) [1 × 10
4 CFU
of VPI 10463], or vehicle, by oro-gastric gavage. Body weight and stool consistency data were collected daily on study days 11 through 16. On
study day 16, mice were euthanized and the colons were removed for measuring morphometric, biochemical and histological indices of colitis.
Figure 2 Mouse survival data. All mice (6/6) that did not receive C. difficile survived for the duration of the study. As shown, 100% of mice
treated with BC30 survived on study day 13, while 2 mice treated with vehicle did not survive on that day (92.3% survival). By day 14, 21/23
mice survived in the BC30/C. difficile treatment group, while 23/26 mice survived in the vehicle/C. difficile treatment group. Therefore, the
cumulative survival rates in the study were: 100% (Vehicle/no C. difficile), 88.5% (Vehicle/C. difficile) and 91.3% (BC30/C. difficile). However, there
was not a statistically significant difference in the survival rate between any of the treatment groups.
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Page 3 of 90.022 ± 0.006 (Vehicle/no C. difficile), 0.048 ± 0.004
(Vehicle/C. difficile) and 0.039 ± 0.004 (BC30/C. diffi-
cile). Specifically, as shown in Figure 6A, the nuclear
binding of NF-B p65 was increased 2.2 fold in the
colons of Vehicle/C. difficile treated mice, but only 1.8
fold in probiotic treated animals. Similarly, the colonic
MIP-2 content was significantly increased in vehicle
treated mice, but the increase was less dramatic in BC30
treated mice (Figure 6B). On study day 16, the MIP-2
values (pg/2 cm colon) were: 10.2 ± 0.5 (Vehicle/no C.
difficile), 24.6 ± 9.5 (Vehicle/C. difficile) and 16.3 ± 4.3
(BC30/C. difficile). Due to the variability in the colonic
MIP-2 values within the Vehicle/C. difficile treatment
group, a statistically significant reduction in the colonic
MIP-2 content was not found with BC30 treatment.
Discussion
Recently, Chen et al. described a murine model of CDAD
that could be used for testing the efficacy of applicable
pharmacological agents (antibiotics, probiotics) [6]. Infec-
tion of female C57BL/6 mice with 10
3 to 10
4 CFU of
C. dififcile was associated with significant weight loss,
diarrhea and mortality [6]. In a similar fashion, we also
showed that the infection of vehicle treated mice resulted
in transient weight loss, altered stool consistency and
some evidence of mortality (11.5%).
In contrast to vehicle treatment, mice treated with the
probiotic (BC30) had a delayed onset in mortality (no
deaths until day 14), as well as a slightly reduced overall
mortality rate (8.7%), when compared to vehicle treated
animals (Figure 2). In a similar fashion, mice treated with
B C 3 0h a dad e l a y e do n s e ti nthe appearance of altered
stool consistency (Figure 3). Specifically, on day 12, 87%
of vehicle treated mice had evidence of loose stools or
diarrhea. In contrast, only 33% of BC30 treated animals
had evidence of altered stool consistency (p < 0.05 vs.
vehicle). Moreover, on the final study day (day 16), BC30
treated mice still had a higher incidence of normal stools
Figure 3 Stool consistency data. All mice that did not receive C. difficile had normal stools throughout the study. In contrast, only 13% of
mice in the Vehicle/C. difficile treatment group had normal stools on day 12, while 67% of the BC30 treated mice still had normal stools. On
days 13 and 14, altered stool consistency was seen in both C. difficile treatment groups. However, evidence of a normal stool was seen in 24% of
BC30 treated mice on day 16, but no vehicle treated animals (0%) showed a normal stool consistency on that day. Statistical significance (* p <
0.05) between the vehicle and BC30 treatment groups was found on study days 12 and 16.
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tency score (Figure 4). These results demonstrate evi-
dence of improved stool consistency in C. difficile
infected mice that were pre-treated with BC30.
Murine CDAD is associated with a specific colonic his-
topathology that includes crypt damage, submucosal
edema and the influx of inflammatory cells [6]. These
pathological changes were also evident in our Vehicle/C.
diificle treated cohort of mice (panel B, Figure 5). In con-
trast, mice treated with BC30 showed some evidence of
attenuated colonic histopathology, including decreased
leukocyte influx into the colon (panel C, Figure 5). How-
ever, the overall comparisons of mean colonic histology
scores were not statistically different on day 16.
Data from other studies suggests that toxin A secreted
by C. difficile can activate the NF-B signal transduction
system in monocytes and colonic epithelial cells [4,5].
This activation of NF-B leads to the secretion of a key
pro-inflammatory chemokine (IL-8) and subsequently
neutrophil influx into the colonic tissue [4,5]. Interest-
ingly, BC-30 can significantly inhibit the IL-8 directed
migration of human neutrophils in vitro [19]. Based on
these results, we measured the effects of BC30 on the
nuclear binding of NF-Bp 6 5 ,a sw e l lt h em u r i n ec h e -
mokine (MIP-2) content in the colons of C. difficile
infected mice. Probiotic treatment resulted in reductions
of both colonic p65, as well as the MIP-2 content (Figure
6). However, statistical significance was not achieved
compared to values in vehicle treated mice.
Nevertheless, these effects of BC30 on NF-B mediated
pathological processes (Figure 6) may contribute to the
observed improvement in stool consistency observed in
the probiotic-treated mice. For example, NF-B activa-
tion is involved in the up-regulation of Fas-ligand, which
subsequently leads to colonocyte apoptosis [20]. Colono-
cyte apoptosis could diminish the barrier function of the
colonic mucosa, and contribute to the altered stool con-
sistency associated with CDAD [20]. By reducing the
colonic activation of NF-B (Figure 6), it is possible that
BC-30 treatment improved the barrier function of the
c o l o n i cm u c o s a( F i g u r e5 C ) ,thereby improving stool
consistency (Figures 2 and 3). Possibly, the improvement
in stool consistency was unrelated to direct effects on
colonization of C. difficile, or an alteration in the produc-
tion of toxins A and B, because all infected mice showed
evidence of infection and exotoxin production by ELISA
Figure 4 Stool consistency score data. The mean stool consistency scores for the three cohorts of mice on day 16 were: 0 ± 0 (Vehicle/No C.
difficile), 1.9 ± 0.2 (Vehicle/C. difficile) and 1.1 ± 0.2 (BC30/C. difficile). * indicates p < 0.05 vs. Vehicle/no C. difficile. + indicates p < 0.05 vs. Vehicle/
C. difficile.
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this study does not quantify either the numbers of C. dif-
ficile in the colon, or the actual amounts of toxin produc-
tion. Therefore, it is also possible that BC30 attenuated
the level of C. difficile colonization and/or production of
toxins in the colon. Future studies are needed to better
understand the mechanisms, by which BC30 favorably
impact stool consistency, as we observed in this study.
Of importance to this study, it is probable that the use
of antibiotics in this murine CDAD model (during study
days 5 to 10) resulted in anti-microbial effects that
altered the levels of BC30 in the colon (David Keller,
personal communication). Therefore, future studies with
this murine model of CDAD should focus on effects of
BC30 on the recurrence of C. difficile following treat-
ment with vancomycin [6]. Using this recurrence para-
digm, the unwanted anti-microbial effects of antibiotics
will not negatively impact the presence of BC-30 in the
mouse colon. Finally, it would also be interesting to test
other Bacillus coagulans strains in this type of experi-
mental paradigm.
Conclusions
The probiotic BC30 improved some parameters of C. diffi-
cile-induced colitis in mice. BC30 prolonged the survival
of C. diffiicle infected mice. Particularly, this probiotic
A
B
C
Figure 5 Representative colonic histology pictures (day 16). The pictures are from hematoxylin and eosin (H&E) stained colonic specimens,
at a magnification of 200-fold. Panel A shows a normal histological appearance within the colon of a mouse that was not infected with C.
difficile. Panel B is from the colon of a Vehicle/C. difficile treated mouse. There is evidence of crypt damage, submucosal edema and the influx of
inflammatory cells in the lamina propria and sub-mucosa. Panel C is from the colon of a BC30/C. difficile treated animal. Although, colonic
pathology is still present, it is less prominent than in panel B.
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colitis model. Our results support the concept that probio-
tics like BC30 may find a niche for the treatment of
CDAD.
Methods
Bacillus Coagulans GBI-30, 6086 (BC30)
BC30 was obtained from Ganeden Biotech Inc. (May-
field Heights, OH).
Murine Clostridium difficile-Induced Colitis
We followed the protocol developed by Chen et al.,
with slight modifications [6]. BC30 (2 × 10
9 CFU per
day), or vehicle (0.9% saline), was dosed by oro-gastric
gavage from study day 0 until study day 15. Both body
weight and stool consistency data were collected daily
on study days 11 through 16. Stool samples from all
mice were scored based on the consistency of the fecal
s a m p l e ,a ss h o w nh e r e :0=n o r m a l ,1=l o o s es t o o l ,
Figure 6 Panel A shows the colonic NF-Bp 6 5d a t a . The mean absorbance values for p65 binding were: 0.022 ± 0.006 (Vehicle/no C.
difficile), 0.048 ± 0.004 (Vehicle/C. difficile) and 0.039 ± 0.004 (BC30/C. difficile). The * symbol indicates p < 0.05 vs. Vehicle/no C. difficile. Panel B
shows the colonic MIP-2 chemokine data. The MIP-2 values (pg/2 cm colon) were: 10.2 ± 0.5 (Vehicle/no C. difficile), 24.6 ± 9.5 (Vehicle/C. difficile)
and 16.3 ± 4.3 (BC30/C. difficile).
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Page 7 of 92 = loose/some diarrhea, 3 = diarrhea and 4 = severe
watery diarrhea.
On day 16, we confirmed the presence of Clostridium
difficile and associated toxins (A and B) with a Wam-
pole™ CD quick check complete kit from Inverness
Medical (Princeton, NJ). On this study day, mice were
euthanized; and the distal colon was collected for evalu-
ating morphometric (colon weight), histological and bio-
chemical parameters. An overview of the study design is
shown in Figure 1. This protocol was approved by the
Internal Animal Care and Use Committee (IACUC) at
the Penn State College of Medicine.
Colonic Histology Evaluation
Using coded slides from the distal colon, four areas
from each slide were scored on a three-point severity
scale: 0 = Normal, 1 = Mild, 2 = Moderate, 3 = Severe,
for three different parameters. These three parameters
were epithelial damage, mucosal/submucosal edema and
leukocyte infiltration. Therefore, the total score for each
slide (i.e., mouse) was between 0 and 9.
Colonic NF-B p65 Assay
We utilized a TransAM™ NF-B p65 assay kit from
Active Motif (Carlsbad, CA). This assay measures the
nuclear binding of p65 to a consensus NF-Bb i n d i n g
site. For the assay, we used 20 μgo fp r o t e i nf r o mc o l o -
nic nuclear extracts. The results are expressed as the
absorbance at 450 nm, as described previously by our
laboratory [15].
Colonic MIP-2 Content
MIP-2 (macrophage inflammatory protein-2) is a func-
tional murine homolog of the human chemokine, IL-8.
The colonic MIP-2 content was measured with an
ELISA kit from R&D systems (Minneapolis, MN).
Results are expressed as pg/2 cm colon.
Statistical Analyses
Statistical analyses were done with a GraphPad Prism
®
software program (San Diego, CA). All data are expressed
as the mean ± SEM. Differences in mouse survival, as well
as the percentages of mice with normal stools, were deter-
mined with the Fisher’s exact test. Stool consistency scores
and colonic histology scores were evaluated with the Krus-
kal-Wallace test, followed by Dunn’s test to compare indi-
vidual treatment groups. All other parameters were
evaluated by ANOVA, followed by the Newman Keuls test
for individual treatment groups. A p value of < 0.05 was
considered to be statistically significant for all parameters.
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